Mitsubishi Tanabe Of Japan, Vertex Of U.S. Change Hepatitis C Pact
This article was originally published in PharmAsia News
Executive SummaryJapan's Mitsubishi Tanabe Pharma and U.S.-based Vertex Pharmaceuticals have revised their licensing agreement for the MP-424 (peginterferon) drug to treat hepatitis C. The drug is still in Phase III Japanese trials, but the companies decided a change was needed to help get the drug through those trials. Under the new arrangement, Mitsubishi Tanabe is to pay Vertex $105 million for a license to use the trial data to develop the drug for use in combination with interferon to treat hepatitis C. The new agreement eliminates royalties linked to sales. (Click here for more - a subscription may be required
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.